Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cellectar Biosciences, Inc. - Common Stock (NQ:CLRB)

3.510 -0.080 (-2.23%)
Streaming Delayed Price Updated: 10:47 AM EDT, Oct 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 87,518
Open 3.610
Bid (Size) 3.460 (31)
Ask (Size) 3.560 (1)
Prev. Close 3.590
Today's Range 3.400 - 3.610
52wk Range 3.530 - 66.00
Shares Outstanding 1,812,040
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma
CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression Free Survival and Overall Survival 
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research
CLR 225 (225Ac-phospholipid ether) Demonstrates Meaningful Inhibition of Tumor Growth and Potential Survival Benefit In Three Pancreatic Cancer Xenograft Models 
From Cellectar Biosciences, Inc.
Via GlobeNewswire

Performance

YTD
-64.0%
-64.0%
1 Month
-35.1%
-35.1%
3 Month
-30.2%
-30.2%
6 Month
-60.5%
-60.5%
1 Year
-94.3%
-94.3%

More News

Read More
Earnings Scheduled For August 14, 2025
Via Benzinga
A Peek at Cellectar Biosciences's Future Earnings
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Cellectar Biosciences Stock Drops 17% On $5.8M Fundraise: Retail Awaits An ‘Impending’ Rally
Via Stocktwits
Topics Supply Chain
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM)
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC)
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Cuts Q2 Losses and Expenses
Via The Motley Fool
Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025
From Cellectar Biosciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option
From Cellectar Biosciences, Inc.
Via GlobeNewswire
Which stocks are moving on Tuesday?
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Which stocks are experiencing notable movement on Tuesday?
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session.
Via Chartmill
Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering
From Cellectar Biosciences, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Cellectar Biosciences, Inc. - Common Stock publicly traded?
Yes, Cellectar Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Cellectar Biosciences, Inc. - Common Stock trade on?
Cellectar Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Cellectar Biosciences, Inc. - Common Stock?
The ticker symbol for Cellectar Biosciences, Inc. - Common Stock is CLRB on the Nasdaq Stock Market
What is the current price of Cellectar Biosciences, Inc. - Common Stock?
The current price of Cellectar Biosciences, Inc. - Common Stock is 3.510
When was Cellectar Biosciences, Inc. - Common Stock last traded?
The last trade of Cellectar Biosciences, Inc. - Common Stock was at 10/28/25 10:47 AM ET
What is the market capitalization of Cellectar Biosciences, Inc. - Common Stock?
The market capitalization of Cellectar Biosciences, Inc. - Common Stock is 6.36M
How many shares of Cellectar Biosciences, Inc. - Common Stock are outstanding?
Cellectar Biosciences, Inc. - Common Stock has 6M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.